EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Cognitive & Neuroprotective Peptides
Nootropic peptides—cognitive peptides used for memory, attention, and mood—attract a different research audience than most clusters on this site, one that skews toward self-experimentation, often with a higher tolerance for preclinical-only evidence. This cluster contains some of the most aggressively marketed compounds on Peptidings alongside some of the most scientifically rigorous failures.
This cluster contains two compounds with Phase II or Phase III Western clinical data, two Russia-approved compounds with meaningful but geographically limited evidence, three preclinical-only compounds popular in self-experimentation communities, a century-old synthetic dye, and a mystery peptide whose gene and receptor remain unknown. Evidence tier placement is based on published human data, not popularity.
Cluster at a Glance
|
10 Compounds Covered |
2 Clinical Trials |
4 Pilot Data |
3 Preclinical |
1 It’s Complicated |
|
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
It’s Complicated Mixed evidence or classification issues |
BLUF: Bottom Line Up Front
Cerebrolysin and NAP (Davunetide) have the most rigorous evidence—both reached Phase II/III Western clinical trials, both failed primary endpoints, and both remain scientifically credible despite those failures. Selank and Semax are Russia-approved nootropics with real pharmaceutical histories and plausible mechanisms, but zero Western regulatory data. Below those four, the evidence drops sharply: Dihexa, P21, and PE-22-28 are single-lab preclinical compounds the community uses based on mechanistic excitement rather than clinical evidence. Methylene Blue is a 150-year-old dye—not a peptide—with genuine cognitive effects and dangerous drug interactions. DSIP is a 50-year mystery whose gene and receptor have never been identified.
In This Article
Compounds in This Cluster
All 10 compounds in the Cognitive & Neuroprotective Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 5
The Russian Nootropic Twins
Both from the Institute of Molecular Genetics in Moscow, both heptapeptides with Pro-Gly-Pro stabilizing tails, both approved in Russia as nasal sprays. Selank targets anxiety (tuftsin-derived, GABAergic). Semax targets cognition (ACTH-derived, BDNF-upregulating). The best-evidenced peptide nootropics available.
Group 2 of 5
The Failed Pharma Candidates
Both reached Phase 2/3 clinical trials for neurodegenerative diseases. Both had their largest trials fail. Cerebrolysin for stroke (CASTA, N=1,070). NAP for PSP (N=313). Both illustrate the enormous difficulty of translating neuroprotection from animal models to human diseases.
|
|
Group 3 of 5
The Preclinical Frontier
Zero human data for any of them. Each from a single respected academic lab with a coherent scientific program. These are the compounds the community uses based on mechanistic excitement rather than clinical evidence.
|
|
|
Group 4 of 5
The Brain Extract
Cortexin belongs to the same intellectual tradition as Cerebrolysin—tissue-derived peptide extracts from the Khavinson bioregulation school. It is one of the most commonly prescribed neuroprotective agents in Russian clinical practice, with almost no rigorous Western evidence.
|
Group 5 of 5
The Odd Ones Out
Neither fits neatly with the peptide nootropics. Methylene Blue is a 150-year-old synthetic dye—not a peptide—with genuine memory-enhancing effects. DSIP is a 50-year mystery whose gene and receptor remain unknown.
|
|
How These Compounds Relate
The ten compounds in this cluster operate through distinct mechanisms that address different aspects of cognitive and neurological function. Cerebrolysin and NAP (Davunetide) are the most clinically studied—both have Phase II or Phase III Western trial data, both have failed primary endpoints in at least one major trial, and both remain scientifically credible despite those failures. A compound that completes rigorous Phase II/III trials and does not meet its primary endpoint is providing more useful information than a compound that has never been tested in humans at all.
Selank and Semax are the most widely self-experimented peptides in this cluster in Western communities, despite their evidence base being primarily Russian. Both are Russia-approved, both have intranasal delivery that achieves CNS bioavailability without injection, and both have plausible and well-characterized mechanisms. The absence of Western Phase II trials does not mean the Russian clinical data is fabricated—it means it has not been independently replicated in a Western regulatory context.
The preclinical compounds (Dihexa, P21, PE-22-28) each come from a single respected academic lab with a coherent research program. They share a common pattern: striking mechanistic data, a single group of investigators, and zero human pharmacokinetic or safety data. The gap between “this grew neurons in a mouse” and “this is safe and effective in a human brain” is not a technicality—it is where most neuroscience drug candidates die.
| Shared Mechanism | Compounds |
|
BDNF / Neurotrophic Upregulation Increasing brain-derived neurotrophic factor or similar growth factors to support neuron survival and plasticity. |
Semax, Selank, Cerebrolysin |
|
Microtubule Stabilization Protecting the structural scaffolding inside neurons—relevant to tauopathies like Alzheimer’s and PSP. |
NAP (Davunetide), P21 Peptide |
|
Synaptogenesis / HGF Pathway Triggering new synapse formation through hepatocyte growth factor receptor (c-Met) activation. |
Dihexa |
|
GABAergic / Anxiolytic Modulation Enhancing inhibitory neurotransmission to reduce anxiety without sedation or dependence. |
Selank, DSIP |
|
Ion Channel Modulation Blocking TREK-1 potassium channels to trigger rapid neurogenesis—a mechanism distinct from traditional antidepressants. |
PE-22-28 |
Plain English
Two compounds here went through the full Western clinical trial process and failed their biggest tests—but that failure is more informative than compounds that have never been tested in humans at all. Two Russian-approved nasal sprays have real pharmaceutical histories. Three single-lab preclinical compounds are popular in self-experimentation communities despite having zero human data. And one compound (Methylene Blue) is a 150-year-old dye that happens to improve memory.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.